Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
December 09, 2023 13:30 ET
|
Cogent Biosciences, Inc.
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated...
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
December 07, 2023 09:00 ET
|
Cogent Biosciences, Inc.
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently...
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
December 04, 2023 08:00 ET
|
Cogent Biosciences, Inc.
- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced...
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
November 29, 2023 08:00 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
November 02, 2023 09:00 ET
|
Cogent Biosciences, Inc.
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2...
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2023 12:30 ET
|
Cogent Biosciences, Inc.
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 08, 2023 08:00 ET
|
Cogent Biosciences, Inc.
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023 Enrollment for Phase 3 PEAK trial in GIST continues on...
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
June 09, 2023 16:01 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
June 07, 2023 09:00 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., June 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
June 06, 2023 20:25 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...